Added to YB: 2026-03-03
Pitch date: 2026-02-28
BMY [neutral]
Bristol-Myers Squibb Company
-1.84%
current return
Author Info
Max Dividends focuses on high yield & dividend growth stocks in their newsletter. Sign up for the newsletter.
Company Info
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
Market Cap
$127.0B
Pitch Price
$62.37
Price Target
57.64 (-6%)
Dividend
4.04%
EV/EBITDA
8.36
P/E
18.02
EV/Sales
3.38
Sector
Pharmaceuticals
Category
dividend
Bristol Myers Squibb: A Reliable Dividend Pharma Giant
BMY (overview): Major pharma w/ oncology focus (Opdivo), 4.63% yield, $2.52/share annual dividend. 17-yr dividend growth streak, 7.91% 5-yr CAGR. 85% payout ratio sustainable. FY24 rev $48.3B (+7% YoY), non-GAAP EPS $1.15. Growth portfolio (Reblozyl, Breyanzi) offsetting patent expirations. Pipeline: 10+ new drugs by 2030, BMS-986446 for Alzheimer's, milvexian for stroke. 14 analysts 'Buy' consensus, $57.64 PT (+5.76% upside). Risks: high payout ratio limits flexibility, generic competition.
Read full article (6 min)